PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 25651378-1 2015 Fentanyl is primarily metabolized by CYP3A, but has also been suggested to act as a weak inhibitor of CYP3A. Fentanyl 0-8 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 37-42 25651378-1 2015 Fentanyl is primarily metabolized by CYP3A, but has also been suggested to act as a weak inhibitor of CYP3A. Fentanyl 0-8 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 102-107 25651378-2 2015 We investigated the influence of CYP3A inhibition by ketoconazole on the pharmacokinetics of intravenously administered fentanyl and the effect of fentanyl on CYP3A activity. Fentanyl 147-155 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 159-164 25651378-13 2015 Clinically fentanyl dosage adjustments may become necessary when ketoconazole or other strong CYP3A inhibitors are given simultaneously. Fentanyl 11-19 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 94-99 25176283-6 2015 Fentanyl is N-dealkylated by CYP3A4 into the inactive norfentanyl. Fentanyl 0-8 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 29-35 26088794-0 2015 CYP3A4 * 1G Genetic Polymorphism Influences Metabolism of Fentanyl in Human Liver Microsomes in Chinese Patients. Fentanyl 58-66 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 0-6 26088794-1 2015 PURPOSE: This study aimed to investigate whether CYP3A4*1G genetic polymorphism influences the metabolism of fentanyl in human liver microsomes in Chinese patients. Fentanyl 109-117 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 49-55 26088794-12 2015 There was positive correlation between CYP3A4 mRNA and metabolic rate of fentanyl (p < 0.01). Fentanyl 73-81 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 39-45 26088794-13 2015 CONCLUSIONS: CYP3A4*1G genetic polymorphism decreases the metabolism of fentanyl. Fentanyl 72-80 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 13-19 26088794-14 2015 There is a positive correlation between CYP3A4 mRNA level and metabolism of fentanyl. Fentanyl 76-84 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 40-46 25948306-8 2015 The activities of CYP3A, ABCB1, and OPRM1 contribute to the interindividual variations in clinical responses to fentanyl in cancer patients. Fentanyl 112-120 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 18-23 24333052-0 2014 Effect of ritonavir-induced cytochrome P450 3A4 inhibition on plasma fentanyl concentrations during patient-controlled epidural labor analgesia: a pharmacokinetic simulation. Fentanyl 69-77 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 28-47 24469018-1 2014 OBJECTIVE: This study aimed to investigate whether CYP3A4/5 genetic variants, together with clinical and patient factors, influence serum fentanyl and norfentanyl concentrations and their ratio in cancer pain patients receiving transdermal fentanyl. Fentanyl 138-146 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 51-57 24469018-1 2014 OBJECTIVE: This study aimed to investigate whether CYP3A4/5 genetic variants, together with clinical and patient factors, influence serum fentanyl and norfentanyl concentrations and their ratio in cancer pain patients receiving transdermal fentanyl. Fentanyl 154-162 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 51-57 24469018-3 2014 Using stepwise linear regression, CYP3A4/5 genetic variability was examined in combination with patient factors relating to organ drug elimination function and ABCB1 genetics for their association with serum fentanyl and norfentanyl concentrations and metabolic ratio (MR) (norfentanyl : fentanyl). Fentanyl 208-216 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 34-40 24469018-8 2014 CYP3A4*22 and CYP3A5*3 genotypes, and multiple clinical factors, combine to influence transdermal fentanyl pharmacokinetics, but accounted for only a small proportion of variability in this study. Fentanyl 98-106 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 0-6 24333052-1 2014 BACKGROUND: Ritonavir inhibition of cytochrome P450 3A4 decreases the elimination clearance of fentanyl by 67%. Fentanyl 95-103 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 36-55 23557865-3 2013 The aim of this study was to investigate the association between postoperative fentanyl consumption and genetic polymorphisms of mu-opioid receptor (OPRM1), ABCB1 (gene encoding P-glycoprotein), CYP3A4 and CYP3A5 in Korean patients. Fentanyl 79-87 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 195-201 24161162-0 2013 Impact of CYP3A and ABCB1 polymorphisms on the pharmacokinetics and pharmacodynamics of fentanyl. Fentanyl 88-96 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 10-15 21535061-0 2012 Effect of CYP3A4*1G on the fentanyl consumption for intravenous patient-controlled analgesia after total abdominal hysterectomy in Chinese Han population. Fentanyl 27-35 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 10-16 23313934-1 2013 The present study aimed to investigate the effect of cytochrome P450 3A4 (CYP3A4)*18B polymorphisms and the interaction of the micro opioid receptor gene (OPRM1) A118G and CYP3A4*18B polymorphisms on postoperative fentanyl analgesia in Chinese Han patients undergoing radical gastrectomy. Fentanyl 238-246 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 196-202 23313934-6 2013 In the first 48 h following surgery, patients in the CYP3A4*18B/*18B group consumed significantly less fentanyl compared with patients in the *1/*1 group (P=0.032). Fentanyl 115-123 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 65-71 23313934-9 2013 Results demonstrated that 48 h following surgery, patients with the CYP3A4*18B/*18B genotype required less fentanyl than patients with the CYP3A4*1/*1 genotype to control pain. Fentanyl 119-127 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 68-74 23313934-10 2013 Additionally, the combined genotype of CYP3A4*18B and OPRM1 A118G may affect fentanyl doses administered for pain control, but not postoperative nausea, vomiting and dizziness. Fentanyl 89-97 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 39-45 23257955-4 2013 Since fentanyl is predominantly metabolized by the drug-metabolizing enzyme cytochrome P450 (CYP) 3A4 in the liver, its concentration may vary in cases of physiologically reduced CYP3A4 activity in the liver (liver disease and aging) or on co-administration of drugs. Fentanyl 6-14 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 76-101 23257955-4 2013 Since fentanyl is predominantly metabolized by the drug-metabolizing enzyme cytochrome P450 (CYP) 3A4 in the liver, its concentration may vary in cases of physiologically reduced CYP3A4 activity in the liver (liver disease and aging) or on co-administration of drugs. Fentanyl 6-14 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 179-185 22764844-4 2012 Based upon this evaluation, Child-Pugh Score and use of a cytochrome P450 3A4 (CYP3A4) inducer were identified as the most significant factors in variations in serum fentanyl concentration and incorporated into the following Final Model formula: CL(fenta) (L/h) = 3.53 x (15 - Child-Pugh Score) x (1 + 1.38 x use or no use of CYP3A4 inducer). Fentanyl 166-174 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 58-77 22764844-4 2012 Based upon this evaluation, Child-Pugh Score and use of a cytochrome P450 3A4 (CYP3A4) inducer were identified as the most significant factors in variations in serum fentanyl concentration and incorporated into the following Final Model formula: CL(fenta) (L/h) = 3.53 x (15 - Child-Pugh Score) x (1 + 1.38 x use or no use of CYP3A4 inducer). Fentanyl 166-174 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 79-85 22764844-4 2012 Based upon this evaluation, Child-Pugh Score and use of a cytochrome P450 3A4 (CYP3A4) inducer were identified as the most significant factors in variations in serum fentanyl concentration and incorporated into the following Final Model formula: CL(fenta) (L/h) = 3.53 x (15 - Child-Pugh Score) x (1 + 1.38 x use or no use of CYP3A4 inducer). Fentanyl 166-174 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 326-332 21535061-2 2012 Cytochrome P450 3A4 (CYP3A4) is the main metabolism enzyme of fentanyl, and single nucleotide polymorphisms within the CYP3A4 gene may contribute to the variability of fentanyl analgesic efficacy. Fentanyl 62-70 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 0-19 21535061-2 2012 Cytochrome P450 3A4 (CYP3A4) is the main metabolism enzyme of fentanyl, and single nucleotide polymorphisms within the CYP3A4 gene may contribute to the variability of fentanyl analgesic efficacy. Fentanyl 62-70 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 21-27 21535061-2 2012 Cytochrome P450 3A4 (CYP3A4) is the main metabolism enzyme of fentanyl, and single nucleotide polymorphisms within the CYP3A4 gene may contribute to the variability of fentanyl analgesic efficacy. Fentanyl 62-70 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 119-125 21535061-2 2012 Cytochrome P450 3A4 (CYP3A4) is the main metabolism enzyme of fentanyl, and single nucleotide polymorphisms within the CYP3A4 gene may contribute to the variability of fentanyl analgesic efficacy. Fentanyl 168-176 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 0-19 21535061-2 2012 Cytochrome P450 3A4 (CYP3A4) is the main metabolism enzyme of fentanyl, and single nucleotide polymorphisms within the CYP3A4 gene may contribute to the variability of fentanyl analgesic efficacy. Fentanyl 168-176 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 21-27 21535061-2 2012 Cytochrome P450 3A4 (CYP3A4) is the main metabolism enzyme of fentanyl, and single nucleotide polymorphisms within the CYP3A4 gene may contribute to the variability of fentanyl analgesic efficacy. Fentanyl 168-176 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 119-125 21535061-3 2012 The aim of this study was to investigate whether the most common genetic variation in Chinese, CYP3A4*1G, has an impact on the fentanyl consumption for intravenous PCA in Chinese Han women undergone abdominal total hysterectomy. Fentanyl 127-135 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 95-101 21535061-14 2012 WHAT IS NEW AND CONCLUSIONS: CYP3A4*1G has an impact on the analgesic effect of fentanyl in Chinese Han subjects. Fentanyl 80-88 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 29-35 16419387-9 2005 The mean fentanyl concentration and metabolic ratio of fentanyl to norfentanyl of the 2 cases with CYP3A4*1B and CYP3A5*3 variants were 12.8 and 1.4 microg/L, respectively, lower than those of 22 cases with wild type CYP3A4*1B and CYP3A5*3 homozygous variants, 16.7 and 7.3 microg/L, respectively. Fentanyl 9-17 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 99-105 21128989-2 2012 In this study, we investigated the association between cytochrome P450 3A4 (CYP3A4) genetic polymorphisms and post-operative fentanyl requirements. Fentanyl 125-133 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 55-74 21128989-2 2012 In this study, we investigated the association between cytochrome P450 3A4 (CYP3A4) genetic polymorphisms and post-operative fentanyl requirements. Fentanyl 125-133 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 76-82 19784640-0 2010 CYP3A4*1G genetic polymorphism influences CYP3A activity and response to fentanyl in Chinese gynecologic patients. Fentanyl 73-81 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 0-6 19784640-0 2010 CYP3A4*1G genetic polymorphism influences CYP3A activity and response to fentanyl in Chinese gynecologic patients. Fentanyl 73-81 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 0-5 19784640-1 2010 PURPOSE: To investigate whether the CYP3A4*1G genetic polymorphism contributes to the variability in CYP3A activity and response to fentanyl. Fentanyl 132-140 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 36-42 19784640-1 2010 PURPOSE: To investigate whether the CYP3A4*1G genetic polymorphism contributes to the variability in CYP3A activity and response to fentanyl. Fentanyl 132-140 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 36-41 19784640-10 2010 The patients with the CYP3A4*1G/*1G genotype needed less fentanyl (227.8 +/- 55.2 microg) to achieve pain control than patients carrying the CYP3A4*1/*1 (381.6 +/- 163.6 microg) and CYP3A4*1/*1G (371.9 +/- 180.1 microg) genotypes (P < 0.05) during the first 24 h postoperatively. Fentanyl 57-65 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 22-28 19784640-12 2010 CONCLUSIONS: CYP3A4*1G genetic polymorphism decreases CYP3A activity and fentanyl consumption for postoperative pain control. Fentanyl 73-81 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 13-19 19784640-12 2010 CONCLUSIONS: CYP3A4*1G genetic polymorphism decreases CYP3A activity and fentanyl consumption for postoperative pain control. Fentanyl 73-81 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 13-18 17987285-1 2008 OBJECTIVE: Fentanyl is a widely used opioid analgesic, which is extensively metabolized by hepatic cytochrome P450 (CYP) 3A. Fentanyl 11-19 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 99-123 17987285-2 2008 Recent reports suggest that concomitant administration of CYP3A inhibitors with fentanyl may lead to dangerous drug interactions. Fentanyl 80-88 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 58-63 21223952-0 2011 Impact of CYP3A4*1G polymorphism on metabolism of fentanyl in Chinese patients undergoing lower abdominal surgery. Fentanyl 50-58 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 10-16 21223952-1 2011 PURPOSE: This study aimed to investigate the impact of CYP3A4*1G genetic polymorphism on metabolism of fentanyl in Chinese patients undergoing lower abdominal surgery. Fentanyl 103-111 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 55-61 21223952-8 2011 After grouping according to the genotype of CYP3A4*1G, plasma fentanyl concentration in the *1/*1 variant (wild-type) group (12.8+-6.5 ng/ml) was significantly lower than that in the *1/*1G group (16.8+-9.0 ng/ml, P<0.01) and the *1G/*1G group (28.1+-9.5 ng/ml, P<0.01). Fentanyl 62-70 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 44-50 21223952-11 2011 CONCLUSIONS: CYP3A4*1G polymorphism is related to the pharmacokinetics of fentanyl, and patients with CYP3A4*1G variant A allele have a lower metabolic rate of fentanyl. Fentanyl 74-82 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 13-19 21223952-11 2011 CONCLUSIONS: CYP3A4*1G polymorphism is related to the pharmacokinetics of fentanyl, and patients with CYP3A4*1G variant A allele have a lower metabolic rate of fentanyl. Fentanyl 74-82 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 102-108 21223952-11 2011 CONCLUSIONS: CYP3A4*1G polymorphism is related to the pharmacokinetics of fentanyl, and patients with CYP3A4*1G variant A allele have a lower metabolic rate of fentanyl. Fentanyl 160-168 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 13-19 21223952-11 2011 CONCLUSIONS: CYP3A4*1G polymorphism is related to the pharmacokinetics of fentanyl, and patients with CYP3A4*1G variant A allele have a lower metabolic rate of fentanyl. Fentanyl 160-168 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 102-108 21223952-12 2011 The specific CYP3A4*1G polymorphism may predict the individual requirement of fentanyl. Fentanyl 78-86 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 13-19 21513075-1 2011 BACKGROUND AND OBJECTIVE: Fentanyl is metabolised by cytochrome P450 (CYP) 3A4 and CYP3A5. Fentanyl 26-34 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 53-78 21513075-2 2011 Our previous work demonstrated that the CYP3A4*1G polymorphism significantly affects the post-operative fentanyl analgesic effect in Chinese women undergoing gynaecological surgery. Fentanyl 104-112 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 40-46 21513075-13 2011 However, combined with CYP3A4*1G polymorphism, post-operative fentanyl consumption at 24 h was significantly lower for the CYP3A5*1/*3 or CYP3A5*3/*3 group than the CYP3A5*1/*1 group. Fentanyl 62-70 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 23-29 16634729-2 2006 Possible causes, such as the inhibition of CYP3A4 induced by cyclosporine causing elevations of serum fentanyl, are discussed. Fentanyl 102-110 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 43-49 16419387-9 2005 The mean fentanyl concentration and metabolic ratio of fentanyl to norfentanyl of the 2 cases with CYP3A4*1B and CYP3A5*3 variants were 12.8 and 1.4 microg/L, respectively, lower than those of 22 cases with wild type CYP3A4*1B and CYP3A5*3 homozygous variants, 16.7 and 7.3 microg/L, respectively. Fentanyl 55-63 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 99-105 12824820-7 2003 RESULTS: In all models tested, ethanol induced CYP3A activity and content, as assessed by the metabolism of fentanyl, a sensitive and specific CYP3A substrate, and Western blot analysis, respectively. Fentanyl 108-116 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 47-52 12824820-10 2003 In the HepG2-CYP3A4 line, incubation with cycloheximide caused a decrease in fentanyl metabolism secondary to a decrease in CYP3A4 levels; this decrease was prevented by coincubation of cycloheximide with ethanol. Fentanyl 77-85 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 13-19 9264313-5 1997 Microsomes prepared from different human liver samples were compared for their abilities to metabolize fentanyl, sufentanil and alfentanil, and it was found that disappearance of the three substrates was well correlated with immunoreactive CYP3A4 contents but not with other CYPs, including CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2D6 and CYP2E1. Fentanyl 103-111 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 240-246 10786743-3 2000 Recent studies have shown that fentanyl is metabolized to norfentanyl via cytochrome P-450 3A4 (CYP3A4). Fentanyl 31-39 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 74-94 10786743-3 2000 Recent studies have shown that fentanyl is metabolized to norfentanyl via cytochrome P-450 3A4 (CYP3A4). Fentanyl 31-39 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 96-102 10786743-4 2000 CYP3A4 is responsible for the metabolism of numerous other therapeutic agents, including those administered concurrently with fentanyl (e.g., nifedipine, lidocaine, erythromycin and cyclosporine). Fentanyl 126-134 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 0-6 10562786-0 1999 Fentanyl inhibits metabolism of midazolam: competitive inhibition of CYP3A4 in vitro. Fentanyl 0-8 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 69-75 10562786-6 1999 Fentanyl competitively inhibited metabolism of midazolam to l"-OH MDZ by CYP3A4, with a Ki of 24.2 (6.8) mumol litre-1, comparable with the Ki obtained in human hepatic microsomes. Fentanyl 0-8 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 73-79 10562786-7 1999 These findings indicate that fentanyl competitively inhibits metabolism of midazolam by CYP3A4. Fentanyl 29-37 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 88-94 12657846-3 2003 This study determined the effects of parecoxib on the pharmacokinetics and pharmacodynamics of the CYP3A substrates fentanyl and alfentanil compared with the CYP3A inhibitor troleandomycin. Fentanyl 116-124 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 99-104 11811955-2 2002 CYP3A4 activity and content were assessed by the metabolism of fentanyl, a CYP3A substrate, and Western blots. Fentanyl 63-71 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 0-6 9311623-0 1997 Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: implications for interindividual variability in disposition, efficacy, and drug interactions. Fentanyl 0-8 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 52-71 9264313-6 1997 Specific known inhibitors of CYP enzymes gave similar results, whereas the use of recombinant human CYP enzymes expressed in yeast provided information about the possible involvement of other CYPs than CYP3A4 in the biotransformation of fentanyl and sufentanil. Fentanyl 237-245 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 202-208 9264313-7 1997 The possible in vivo interaction of fentanyl and sufentanil with other drugs catalyzed by CYP3A4 is also discussed. Fentanyl 36-44 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 90-96 8886601-6 1996 Studies using chemical inhibitors of human P450 enzymes revealed that only agents known to inhibit CYP3A4 (e.g. ketoconazole and erythromycin) were capable of strongly inhibiting (> or = 90%) microsomal fentanyl oxidation. Fentanyl 206-214 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 99-105 8886601-9 1996 Our results indicate that CYP3A4 is the major catalyst involved in fentanyl oxidation to norfentanyl in human liver. Fentanyl 67-75 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 26-32 8886601-10 1996 Alterations in CYP3A4 levels or activity, as well as the concomitant administration of other therapeutic agents metabolized by this P450 enzyme, could lead to marked perturbations in fentanyl disposition and, hence, analgesic response. Fentanyl 183-191 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 15-21 8712396-0 1996 Identification of human liver cytochrome P-450 3A4 as the enzyme responsible for fentanyl and sufentanil N-dealkylation. Fentanyl 81-89 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 30-50 8712396-5 1996 Rates of N-dealkylated metabolite formation significantly correlated with nifedipine oxidation activity (a marker of CYP3A4 activity) for fentanyl and sufentanil (r = 0.93 and 0.87, n = 18, respectively), but not with the oxidation activity for ethoxyresorufin (CYP1A2), S-mephenytoin (CYP2C19), bufuralol (CYP2D6), or chlorzoxazone (CYP2E1). Fentanyl 138-146 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 117-123 8712396-6 1996 Gestodene and troleandomycin (chemical inhibitors of CYP3A4) and antibody to CYP3A4 inhibited N-dealkylation of fentanyl and sufentanil. Fentanyl 112-120 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 53-59 8712396-6 1996 Gestodene and troleandomycin (chemical inhibitors of CYP3A4) and antibody to CYP3A4 inhibited N-dealkylation of fentanyl and sufentanil. Fentanyl 112-120 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 77-83 8712396-8 1996 Recombinant CYP3A4 expressed in Escherichia coli showed N-dealkylation activity of fentanyl and sufentanil, while expressed CYP1A2, 2C10, and 2E1 enzymes did not. Fentanyl 83-91 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 12-18 8712396-9 1996 We conclude that CYP3A4 is responsible for fentanyl and sufentanil N-dealkylation in vitro. Fentanyl 43-51 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 17-23 34877660-0 2022 Effect of CYP3A5 and CYP3A4 Genetic Variants on Fentanyl Pharmacokinetics in a Pediatric Population. Fentanyl 48-56 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 21-27 34877660-2 2022 CYP3A4 and CYP3A5 encode enzymes which metabolize fentanyl; genetic variants in these genes impact fentanyl pharmacokinetics in adults. Fentanyl 50-58 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 0-6 34877660-2 2022 CYP3A4 and CYP3A5 encode enzymes which metabolize fentanyl; genetic variants in these genes impact fentanyl pharmacokinetics in adults. Fentanyl 99-107 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 0-6 34877660-4 2022 The aim of this study is to test the effect of CYP3A5 and CYP3A4 genetic variants on fentanyl PK in children using opportunistically collected samples. Fentanyl 85-93 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 58-64 31601999-2 2019 The high pharmacokinetic variability of fentanyl is assumed to be due to cytochrome P450 3A-mediated (CYP3A) N-dealkylation to norfentanyl in humans. Fentanyl 40-48 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 102-107 34045960-8 2021 Results: The predicted maximum concentration (Cmax), area under the curve of concentration-time (AUC), and clearance (CL) for theophylline (CYP1A2 metabolism pathway) and fentanyl (CYP3A4 metabolism pathway) were within two folds of the observed data. Fentanyl 171-179 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 181-187 34337735-4 2021 RESULTS: Remdesivir is an inhibitor of CYP3A4 and may increase the plasma concentration of CYP3A4 substrates (e.g., fentanyl). Fentanyl 116-124 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 39-45 34337735-4 2021 RESULTS: Remdesivir is an inhibitor of CYP3A4 and may increase the plasma concentration of CYP3A4 substrates (e.g., fentanyl). Fentanyl 116-124 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 91-97 33298744-2 2021 A recently published report demonstrated that fentanyl can reduce the total body clearance of TAC; however, most patients in this study were administered concomitantly with azole antifungal agents, which are known to be strong inhibitors of CYP3A. Fentanyl 46-54 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 241-246 31794512-1 2020 WHAT WE ALREADY KNOW ABOUT THIS TOPIC: The popular herbal medicine, St. John"s wort, is a potent inducer of several cytochrome P450 enzymes, including CYP3A4, which plays a role in the metabolism of fentanyl. Fentanyl 199-207 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 151-157 31794512-6 2020 Fentanyl is metabolized by hepatic CYP3A4 and considered transported by blood-brain barrier P-glycoprotein. Fentanyl 0-8 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 35-41 31168770-12 2019 Coadministration of the known CYP3A4/5 inducers fosphenytoin and/or phenobarbital was associated with significantly increased fentanyl clearance. Fentanyl 126-134 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 30-36 31601999-4 2019 In this small study in palliative cancer patients under real-life clinical conditions, the influence of CYP3A on fentanyl variability was investigated. Fentanyl 113-121 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 104-109 31601999-9 2019 Both clearances showed a weak correlation and hence a minimal influence of CYP3A on fentanyl elimination. Fentanyl 84-92 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 75-80 29363349-2 2018 Fentanyl (metabolized by Cytochrome P450 3A4) and morphine (glucuronidated by UDP-glucuronosyltransferase-2B7) served as model drugs to provide insight in maturation patterns of these enzymes and provide understanding of the impact of non-maturational factors to optimize dosing in infants. Fentanyl 0-8 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 25-44 30371861-4 2019 Fentanyl is a common opiate primarily metabolized by CYP3A4 subtypes. Fentanyl 0-8 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 53-59 30381583-0 2018 Impact of CYP3A4*1G Polymorphism on Fentanyl Analgesia Assessed by Analgesia Nociception Index in Chinese Patients Undergoing Hysteroscopy. Fentanyl 36-44 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 10-16 30381583-13 2018 Conclusion: CYP3A4*1G polymorphism associated with the analgesic efficacy of intraoperative fentanyl in the patients undergoing hysteroscopy under general anesthesia. Fentanyl 92-100 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 12-18 29601950-0 2018 Association between MDR1/CYP3A4/OPRM1 gene polymorphisms and the post-caesarean fentanyl analgesic effect on Chinese women. Fentanyl 80-88 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 25-31 29601950-1 2018 OBJECTIVE: Our study aimed to evaluate the association between the multidrug resistance 1 (MDR1)/cytochrome P450 3A4 (CYP3A4)/mu-opioid receptor (OPRM1) gene polymorphisms and the post-caesarean analgesic effect of fentanyl on Chinese women. Fentanyl 215-223 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 97-116 29601950-1 2018 OBJECTIVE: Our study aimed to evaluate the association between the multidrug resistance 1 (MDR1)/cytochrome P450 3A4 (CYP3A4)/mu-opioid receptor (OPRM1) gene polymorphisms and the post-caesarean analgesic effect of fentanyl on Chinese women. Fentanyl 215-223 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 118-124 29601950-7 2018 Subjects with the CYP3A4*1G/*1G genotype needed less fentanyl to achieve pain control than that needed by subjects carrying the CYP3A4*1/*1 and CYP3A4*1/*1G genotypes in the first post-operative 24 h and 48 h (P < 0.05), and the MAP/HR/Cor/Ang-1 levels gradually decreased immediately after surgery and in the first post-operative 24 h. 3. Fentanyl 53-61 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 18-24 29601950-10 2018 CONCLUSION: These results indicated that the MDR1/CYP3A4/OPRM1 gene polymorphisms influenced the fentanyl consumption and the physiological effects of intravenous analgesia in the Chinese women who received lower segment caesarean section surgeries. Fentanyl 97-105 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 50-56 28226339-5 2017 Clinicians should appreciate that since fentanyl is metabolized mainly via CYP3A4, potential adverse effects can occur with concomitant use of any drug which affects CYP3A4 activity. Fentanyl 40-48 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 75-81 28226339-5 2017 Clinicians should appreciate that since fentanyl is metabolized mainly via CYP3A4, potential adverse effects can occur with concomitant use of any drug which affects CYP3A4 activity. Fentanyl 40-48 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 166-172 28226339-6 2017 Discontinuation of CYP3A4 inducers can also result in an increase in fentanyl plasma concentration. Fentanyl 69-77 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 19-25